<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2105">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155946</url>
  </required_header>
  <id_info>
    <org_study_id>N1534-R</org_study_id>
    <nct_id>NCT02155946</nct_id>
  </id_info>
  <brief_title>Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment</brief_title>
  <official_title>Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aging US population threatens to overwhelm our healthcare infrastructure, especially&#xD;
      since the rate of Alzheimer's disease (AD) alone is expected to triple in the coming decades.&#xD;
      Memory cause functional impairment, reduced quality of life, increased caregiver burnout, and&#xD;
      eventual institutionalization. The diagnosis of mild cognitive impairment (MCI) identifies&#xD;
      those with memory deficits but who remain relatively independent in everyday life. MCI&#xD;
      provides a window for interventions that target memory functioning. The proposed study&#xD;
      focuses specifically on a groundbreaking combination of mnemonic rehabilitation and&#xD;
      non-invasive brain stimulation. The main idea is that brain stimulation can enhance&#xD;
      functioning in the specific brain regions/networks, thereby increasing the patients' ability&#xD;
      to benefit from different types of memory rehabilitation. This will be a randomized,&#xD;
      double-blind study (active vs. fake brain stimulation), that provides multiple treatment&#xD;
      session. Outcome will be examined using both laboratory-based and real-world memory testing&#xD;
      as well as brain imaging. This first-of-its-kind study has the potential to meaningfully&#xD;
      translate more &quot;basic&quot; science findings into neuroanatomically targeted and functionally&#xD;
      meaningful treatments for our aging population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrollment and interactions/interventions are temporarily paused due to COVID-19 and are&#xD;
      expected to resume in the future. This is not a suspension of IRB approval.&#xD;
&#xD;
      The proposed study focuses specifically on a groundbreaking combination of mnemonic&#xD;
      rehabilitation and non-invasive brain stimulation. The main idea is that brain stimulation&#xD;
      can enhance functioning in the specific brain regions/networks, thereby increasing the&#xD;
      patients' ability to benefit from memory rehabilitation. This will be a randomized,&#xD;
      double-blind study (active vs. fake brain stimulation), that provides multiple treatment&#xD;
      session. Outcome will be examined using both laboratory-based and real-world memory testing&#xD;
      as well as brain imaging. This first-of-its-kind study has the potential to meaningfully&#xD;
      translate more &quot;basic&quot; science findings into neuroanatomically targeted and functionally&#xD;
      meaningful treatments for our aging population.&#xD;
&#xD;
      The general purpose of this study is to examine the effects of two types of treatments for&#xD;
      memory impairment in those with mild cognitive impairment (MCI). One form of treatment is&#xD;
      cognitive rehabilitation, which involves teaching new ways to learn and remember information.&#xD;
      The second form of treatment uses a type of electrical brain stimulation called transcranial&#xD;
      direct current stimulation (tDCS) to increase activity in certain brain areas that may be&#xD;
      involved with memory. We will use brain imaging to see whether these treatments changed how&#xD;
      individuals learn and remember information. We will also use cognitive tests and&#xD;
      questionnaires to examine whether memory (and related abilities) changed because of&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Face-name Memory Test Performance</measure>
    <time_frame>change from baseline to post session 5 (day 5 after baseline)</time_frame>
    <description>Raw number of face-name pairs correctly recalled with a maximum of 15 points; higher values are better at each time point. Change at post-session 5 (day 5 after baseline)) calculated relative to baseline performance (positive differences indicate improvement; negative values indicate decline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Object Location Association Memory Test Performance - Cued Recall Condition</measure>
    <time_frame>change from baseline to post session 5 (day 5 after baseline)</time_frame>
    <description>Performance measured using deviation from target position (in centimeters). Higher values indicate worse performance. Change at post-session 5 (day 5 after baseline) calculated relative to baseline performance (positive differences indicate decline; negative values indicate improvement).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI Betaweight Change</measure>
    <time_frame>change from baseline to post session 5 (day 5 after baseline)</time_frame>
    <description>Changes in task related blood oxygen dependent signal (BOLD) activation for the face-name (novel post &gt; novel pre) contrast in the left inferior frontal gyrus (pars triangularis, pars orbitalis, pars opercularis). Data are preliminary betaweights for the above noted contrast. Positive values reflect increased BOLD signal while negative values represent reduced BOLD signal. Not all participants were able to complete fMRI, which explains sample size discrepancies with other outcome measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prose Memory</measure>
    <time_frame>change from baseline to post Session 5 (day 5 after baseline)</time_frame>
    <description>Performance on the Ecological Memory Simulations- Medical Instructions subtest. Raw points where higher values reflect better performance at each time point (0-15 possible points at each time point). Reported values reflect change from baseline (i.e., post-session day 5 vs. baseline) where positive values represent improvement and negative values represent decline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMQ - Strategy Subscale</measure>
    <time_frame>change from baseline to post session 5 (day 5 after baseline)</time_frame>
    <description>Changes on the Multifactorial Memory Questionnaire - strategy subscale. Raw points where higher values reflect better performance at each time point (0-76 possible points at each time point). Reported values reflect change from baseline (i.e., post-session day 5 vs. baseline) where positive values represent improvement and negative values represent decline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spatial Navigation</measure>
    <time_frame>change from baseline to post session 5 (day 5 after baseline)</time_frame>
    <description>Performance on Ecological Memory Simulations routes subtest (serial order). Higher values indicate better performance at each time point (0-9 possible points at each time point). Change from baseline is reported (post-session day 5 vs. baseline) so higher values indicate better recall while negative values indicate decline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Planned (Tertiary) Analyses of Patient-specific Characteristics That Affect Treatment Outcome</measure>
    <time_frame>change from baseline post treatment (within ~ 96 hours of session 5)</time_frame>
    <description>Planned analyses to examine patient specific characteristics that affect treatment efficacy and would be vital for clinical translation at the individual patient level. Effect of level of cognitive functioning, measured via neuropsychological test performance at baseline, will be evaluated on magnitude of change at post-treatment and 3 month follow-up. Scores range from -3 to +3 standard deviations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Electric Field Effects</measure>
    <time_frame>Electrical field is estimated using baseline MRI T1 scan.</time_frame>
    <description>Finite element model based measurement of electric field in the targeted brain regions (Values range from 0 to no theoretical upper limit with higher values reflecting more electrical current; most values will be under 0.5 V/m)</description>
  </other_outcome>
  <other_outcome>
    <measure>Brain Morphology</measure>
    <time_frame>Measured at baseline</time_frame>
    <description>Magnetic Resonance Imaging based measure of brain volume (in percent of intracranial volume; higher values reflect larger brain size)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>active tDCS + mnemonic strategy training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group receives active brain stimulation plus memory rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS + mnemonic strategy training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group receives sham brain stimulation plus memory rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active tDCS + autobiographical memory recall</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group receives active brain stimulation plus reminiscence training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS + autobiographical memory recall</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group receives sham brain stimulation plus reminiscence training</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit</intervention_name>
    <description>Active brain stimulation</description>
    <arm_group_label>active tDCS + autobiographical memory recall</arm_group_label>
    <arm_group_label>active tDCS + mnemonic strategy training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit</intervention_name>
    <description>Sham (placebo)</description>
    <arm_group_label>sham tDCS + autobiographical memory recall</arm_group_label>
    <arm_group_label>sham tDCS + mnemonic strategy training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General inclusion criteria (all patients):&#xD;
&#xD;
          -  All medications stable for approximately 2-3 months;&#xD;
&#xD;
          -  No history of severe mental illness;&#xD;
&#xD;
          -  No current untreated alcohol or substance abuse/dependence;&#xD;
&#xD;
          -  English as native and preferred language;&#xD;
&#xD;
          -  MRI-compatible if taking part in fMRI studies&#xD;
&#xD;
          -  Able to give informed consent.&#xD;
&#xD;
        MCI Inclusion Criteria:&#xD;
&#xD;
        - Diagnosis of amnestic MCI based on criteria set forth by Petersen (2004). Additionally,&#xD;
        other potential causes of cognitive deficit ruled out by the referring physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of neurological disease or injury&#xD;
&#xD;
          -  History of severe mental illness&#xD;
&#xD;
          -  Current untreated alcohol or substance abuse&#xD;
&#xD;
          -  Other conditions may exclude; please discuss with contact&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin M. Hampstead, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Ann Arbor Healthcare System, Ann Arbor, MI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Ann Arbor Healthcare System, Ann Arbor, MI</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <results_first_submitted>March 25, 2022</results_first_submitted>
  <results_first_submitted_qc>August 10, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2022</results_first_posted>
  <last_update_submitted>August 10, 2022</last_update_submitted>
  <last_update_submitted_qc>August 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>Alzheimer's Disease/Dementia</keyword>
  <keyword>Cognitive Disorders</keyword>
  <keyword>Imaging</keyword>
  <keyword>Magnetic Resonance Imaging (MRI)</keyword>
  <keyword>Neurology</keyword>
  <keyword>Physical Medicine &amp; Rehabilitation</keyword>
  <keyword>transcranial direct current stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 1, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02155946/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 1, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02155946/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02155946/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>Group receives active brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>Group receives sham brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
        </group>
        <group group_id="P3">
          <title>Arm 3</title>
          <description>Group receives active brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
        </group>
        <group group_id="P4">
          <title>Arm 4</title>
          <description>Group receives sham brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29">number completed at primary endpoint</participants>
                <participants group_id="P2" count="23">number completed at primary endpoint</participants>
                <participants group_id="P3" count="29">number completed at primary endpoint</participants>
                <participants group_id="P4" count="24">number completed at primary endpoint</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Group receives active brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>Group receives sham brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
        </group>
        <group group_id="B3">
          <title>Arm 3</title>
          <description>Group receives active brain stimulation plus autobiographical memory recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
        </group>
        <group group_id="B4">
          <title>Arm 4</title>
          <description>Group receives sham brain stimulation plus autobiographical memory recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.59" spread="7.31"/>
                    <measurement group_id="B2" value="73.88" spread="6.08"/>
                    <measurement group_id="B3" value="72.31" spread="7.36"/>
                    <measurement group_id="B4" value="74.04" spread="6.2"/>
                    <measurement group_id="B5" value="73.14" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Face-name Memory Test Performance</title>
        <description>Raw number of face-name pairs correctly recalled with a maximum of 15 points; higher values are better at each time point. Change at post-session 5 (day 5 after baseline)) calculated relative to baseline performance (positive differences indicate improvement; negative values indicate decline).</description>
        <time_frame>change from baseline to post session 5 (day 5 after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Group receives active brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Group receives sham brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Group receives active brain stimulation plus autobiographical memory recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Group receives sham brain stimulation plus autobiographical memory recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Face-name Memory Test Performance</title>
          <description>Raw number of face-name pairs correctly recalled with a maximum of 15 points; higher values are better at each time point. Change at post-session 5 (day 5 after baseline)) calculated relative to baseline performance (positive differences indicate improvement; negative values indicate decline).</description>
          <units>pairs correctly recalled</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.98" lower_limit="-1.78" upper_limit=".18"/>
                    <measurement group_id="O2" value=".13" lower_limit="-.70" upper_limit=".97"/>
                    <measurement group_id="O3" value=".05" lower_limit="-.77" upper_limit=".86"/>
                    <measurement group_id="O4" value="-.46" lower_limit="-1.27" upper_limit=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Object Location Association Memory Test Performance - Cued Recall Condition</title>
        <description>Performance measured using deviation from target position (in centimeters). Higher values indicate worse performance. Change at post-session 5 (day 5 after baseline) calculated relative to baseline performance (positive differences indicate decline; negative values indicate improvement).</description>
        <time_frame>change from baseline to post session 5 (day 5 after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Group receives active brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Group receives sham brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Group receives active brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Group receives sham brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Object Location Association Memory Test Performance - Cued Recall Condition</title>
          <description>Performance measured using deviation from target position (in centimeters). Higher values indicate worse performance. Change at post-session 5 (day 5 after baseline) calculated relative to baseline performance (positive differences indicate decline; negative values indicate improvement).</description>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" lower_limit=".54" upper_limit="2.92"/>
                    <measurement group_id="O2" value="-.60" lower_limit="-1.92" upper_limit=".73"/>
                    <measurement group_id="O3" value="1.57" lower_limit=".38" upper_limit="2.77"/>
                    <measurement group_id="O4" value="2.22" lower_limit=".89" upper_limit="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>fMRI Betaweight Change</title>
        <description>Changes in task related blood oxygen dependent signal (BOLD) activation for the face-name (novel post &gt; novel pre) contrast in the left inferior frontal gyrus (pars triangularis, pars orbitalis, pars opercularis). Data are preliminary betaweights for the above noted contrast. Positive values reflect increased BOLD signal while negative values represent reduced BOLD signal. Not all participants were able to complete fMRI, which explains sample size discrepancies with other outcome measures.</description>
        <time_frame>change from baseline to post session 5 (day 5 after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Group receives active brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Group receives sham brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Group receives active brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Group receives sham brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>fMRI Betaweight Change</title>
          <description>Changes in task related blood oxygen dependent signal (BOLD) activation for the face-name (novel post &gt; novel pre) contrast in the left inferior frontal gyrus (pars triangularis, pars orbitalis, pars opercularis). Data are preliminary betaweights for the above noted contrast. Positive values reflect increased BOLD signal while negative values represent reduced BOLD signal. Not all participants were able to complete fMRI, which explains sample size discrepancies with other outcome measures.</description>
          <units>Percent BOLD signal change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".34" lower_limit=".22" upper_limit=".47"/>
                    <measurement group_id="O2" value=".11" lower_limit="-.02" upper_limit=".24"/>
                    <measurement group_id="O3" value=".06" lower_limit="-.08" upper_limit=".19"/>
                    <measurement group_id="O4" value=".01" lower_limit="-.12" upper_limit=".14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prose Memory</title>
        <description>Performance on the Ecological Memory Simulations- Medical Instructions subtest. Raw points where higher values reflect better performance at each time point (0-15 possible points at each time point). Reported values reflect change from baseline (i.e., post-session day 5 vs. baseline) where positive values represent improvement and negative values represent decline.</description>
        <time_frame>change from baseline to post Session 5 (day 5 after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Group receives active brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Group receives sham brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Group receives active brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Group receives sham brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Prose Memory</title>
          <description>Performance on the Ecological Memory Simulations- Medical Instructions subtest. Raw points where higher values reflect better performance at each time point (0-15 possible points at each time point). Reported values reflect change from baseline (i.e., post-session day 5 vs. baseline) where positive values represent improvement and negative values represent decline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" lower_limit="-2.12" upper_limit="-.02"/>
                    <measurement group_id="O2" value="-1.24" lower_limit="-2.42" upper_limit="-.07"/>
                    <measurement group_id="O3" value="-.94" lower_limit="-2" upper_limit=".13"/>
                    <measurement group_id="O4" value="-1.58" lower_limit="-2.74" upper_limit="-.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MMQ - Strategy Subscale</title>
        <description>Changes on the Multifactorial Memory Questionnaire - strategy subscale. Raw points where higher values reflect better performance at each time point (0-76 possible points at each time point). Reported values reflect change from baseline (i.e., post-session day 5 vs. baseline) where positive values represent improvement and negative values represent decline.</description>
        <time_frame>change from baseline to post session 5 (day 5 after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Group receives active brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Group receives sham brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Group receives active brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Group receives sham brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>MMQ - Strategy Subscale</title>
          <description>Changes on the Multifactorial Memory Questionnaire - strategy subscale. Raw points where higher values reflect better performance at each time point (0-76 possible points at each time point). Reported values reflect change from baseline (i.e., post-session day 5 vs. baseline) where positive values represent improvement and negative values represent decline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" lower_limit="-.97" upper_limit="3.8"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-1.6" upper_limit="3.81"/>
                    <measurement group_id="O3" value="-1.9" lower_limit="-4.28" upper_limit=".48"/>
                    <measurement group_id="O4" value="-.5" lower_limit="-3.12" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spatial Navigation</title>
        <description>Performance on Ecological Memory Simulations routes subtest (serial order). Higher values indicate better performance at each time point (0-9 possible points at each time point). Change from baseline is reported (post-session day 5 vs. baseline) so higher values indicate better recall while negative values indicate decline.</description>
        <time_frame>change from baseline to post session 5 (day 5 after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Group receives active brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Group receives sham brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Group receives active brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Group receives sham brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Spatial Navigation</title>
          <description>Performance on Ecological Memory Simulations routes subtest (serial order). Higher values indicate better performance at each time point (0-9 possible points at each time point). Change from baseline is reported (post-session day 5 vs. baseline) so higher values indicate better recall while negative values indicate decline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".59" lower_limit="-.18" upper_limit="1.35"/>
                    <measurement group_id="O2" value=".76" lower_limit="-.09" upper_limit="1.61"/>
                    <measurement group_id="O3" value=".97" lower_limit=".19" upper_limit="1.74"/>
                    <measurement group_id="O4" value=".67" lower_limit="-.17" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Planned (Tertiary) Analyses of Patient-specific Characteristics That Affect Treatment Outcome</title>
        <description>Planned analyses to examine patient specific characteristics that affect treatment efficacy and would be vital for clinical translation at the individual patient level. Effect of level of cognitive functioning, measured via neuropsychological test performance at baseline, will be evaluated on magnitude of change at post-treatment and 3 month follow-up. Scores range from -3 to +3 standard deviations.</description>
        <time_frame>change from baseline post treatment (within ~ 96 hours of session 5)</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Electric Field Effects</title>
        <description>Finite element model based measurement of electric field in the targeted brain regions (Values range from 0 to no theoretical upper limit with higher values reflecting more electrical current; most values will be under 0.5 V/m)</description>
        <time_frame>Electrical field is estimated using baseline MRI T1 scan.</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Brain Morphology</title>
        <description>Magnetic Resonance Imaging based measure of brain volume (in percent of intracranial volume; higher values reflect larger brain size)</description>
        <time_frame>Measured at baseline</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Primary study intervention period (5 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Group receives active brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Group receives sham brain stimulation plus mnemonic strategy training&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
        </group>
        <group group_id="E3">
          <title>Arm 3</title>
          <description>Group receives active brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Active brain stimulation</description>
        </group>
        <group group_id="E4">
          <title>Arm 4</title>
          <description>Group receives sham brain stimulation plus autobiographical recall&#xD;
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit: Sham (placebo)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Benjamin Hampstead</name_or_title>
      <organization>VA Ann Arbor</organization>
      <phone>734-763-9259</phone>
      <email>bhampste@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

